Molecular targets for antifibrotic therapy in liver disease: using magic bullets for crossfire rather than a one-sided shotgun attack by Hellerbrand, Claus
Molecular targets for antiﬁbrotic
therapy in liver disease: using magic
bullets for crossﬁre rather than
a one-sided shotgun attack
Claus Hellerbrand
The c-Jun-N-terminal kinase ( JNK) is a
member of the mitogen-activated protein
kinase (MAPK) family. Upon activation,
JNK regulates various cellular responses,
such as differentiation, proliferation,
migration, the immune reaction and cell
death.1 JNK activation is also involved in
multiple pathways in liver physiology and
disease pathogenesis.2
There are three isoforms of JNK in
mammals. Whereas JNK3 is mainly
expressed in the brain, heart and testis,
JNK1 and JNK2 are expressed in most
cells, including hepatic parenchymal and
non-parenchymal cells. JNK1 and JNK2
have typically been considered to have over-
lapping or redundant functions. However,
it is becoming more and more evident that
the JNK isoforms exhibit diverse effects in
various cell types, depending on the magni-
tude and duration of activation.1
Hepatic ﬁbrosis is a complex and tightly
regulated process that involves various cell
types and pathomechanisms. It can be con-
sidered as a dysregulated wound healing
response to chronic hepatic injury.
Activated hepatic stellate cells (HSCs) are
the primary effector cells responsible for
the extensive extracellular matrix accumu-
lation and scar formation. However, the
situation is more complex, as several add-
itional cell types, including parenchymal,
non-parenchymal, immune inﬁltrating and
bone marrow cells, play an important role
in both the pathogenesis and resolution of
liver ﬁbrosis.3 Furthermore, hepatocellular
proliferation and apoptosis are critical for
tissue regeneration and repair, but when
dysregulated, these processes contribute to
the malignant transformation of hepato-
cytes and the development of hepatocellu-
lar carcinoma (HCC).3 4
Therefore, it is critical to understand the
function of distinct JNK isoforms during
the various phases and in the various cell
types involved in hepatic ﬁbrosis.
Examining jnk1 and jnk2 knockout mice
has helped tease out the separate functions
of these two kinases, and Cre/lox-P
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methods for cell-speciﬁc ablation and bone
marrow chimaeras have enabled the ana-
lysis of JNKs in distinct cell types and
organs. Using these approaches, Zhao
et al5 signiﬁcantly expanded our knowl-
edge on the role of Jnk1 in liver ﬁbrosis
and HSCs. This work builds upon a previ-
ous study by Kluwe et al,6 who had
reported that hepatic ﬁbrosis decreased in
jnk1 deﬁcient mice ( JNK1−/−) but was
unchanged or even increased in the
absence of jnk2 ( JNK2−/−) in two models
of hepatic injury, bile duct ligation or
carbon tetrachloride administration. Using
the same two ﬁbrosis models, Zhao et al5
analysed mice with a hepatocyte-speciﬁc
ablation of Jnk1 in addition to JNK1−/−
mice. Unexpectedly, the deletion of Jnk1 in
hepatocytes had no major impact on the
progression of liver disease, whereas both
models clearly indicated that Jnk1 in non-
hepatocytes was majorly relevant.5
Furthermore, bone marrow transplantation
experiments excluded bone marrow–
derived cells from playing a major role in
the JNK1-dependent effect on ﬁbrogen-
esis.5 In contrast, and similar to the results
observed by Kluwe et al,6 JNK was strongly
activated in myoﬁbroblasts following the
induction of liver ﬁbrosis in murine livers,
as well as in human ﬁbrotic livers.5 The in
vitro deletion of Jnk1 in HSCs reduced the
lifespan and decreased the differentiation
of HSCs into matrix-producing myoﬁbro-
blasts,5 indicating that Jnk1 activation med-
iates the transactivation and inhibits the
apoptosis of HSCs. Together, these data
suggest that JNK1 in HSCs is important
for ﬁbrosis progression in both murine
models. Strikingly, acute and chronic hepa-
tocellular injury was also signiﬁcantly
lower in JNK1−/− but not in mice with a
hepatocyte-speciﬁc JNK-1 ablation,5 also
indicating that JNK1 in hepatocytes fails to
play a role in these pathological effects. In
concordance with these data, another pre-
vious study indicated that isolated JNK1
deﬁciency, as well as compound JNK1 and
JNK2 deﬁciency, reduced hepatic inﬂam-
mation and hepatocancerogenesis follow-
ing exposure to the carcinogen
diethylnitrosamine (DEN) in mice.7 In con-
trast, compound JNK deﬁciency
in hepatocytes does not inhibit HCC
but indeed increased the tumour burden in
the DEN model.7 This puzzling
ﬁnding indicates that the carcinogenic
effects of JNK might be restricted to
non-parenchymal cells rather than
hepatocytes, in which it even functions to
reduce tumour development. One can only
speculate which non-parenchymal cells are
responsible for the anti-HCC effect, but
given the known role of activated HSCs in
HCC development and progression,4 their
contribution appears likely.
Despite the important ﬁndings pre-
sented by Zhao et al,5 their study leaves
some open questions. Therefore, the
general isoform-speciﬁc functions of
JNK2 in HSC and hepatic ﬁbrosis remain
unclear. However, the study by Kluwe
et al6 raises an alarm regarding indiscrim-
inate JNK inhibition and—together with
the present study by Zhao et al5—under-
scores that the selective inhibition of the
JNK1 isoform could offer an effective
treatment for hepatic ﬁbrosis.
A therapeutic approach of global JNK
inhibition may be even more problematic in
non-alcoholic fatty liver disease (NAFLD),
in which the distinct functions of JNK1 and
JNK2 have been clearly delineated.8 Thus,
Jnk2-deﬁcient mice placed on a high-fat
diet (HFD) presented a similar degree of
hepatic steatosis as wild-type mice, but had
more severe hepatocellular injury, more
advanced obesity and insulin resistance. In
contrast, HFD-induced hepatocyte injury
and steatosis were suppressed in
Jnk1-deﬁcient mice. However, the
hepatocyte-speciﬁc ablation of jnk1 does
not protect mice from HFD-induced
insulin resistance, but on normal diets,
these mice exhibit increased lipogenesis,
attenuated insulin resistance and the spon-
taneous development of hepatic steatosis.8
On the one hand, these ﬁndings indicate an
anti-steatotic and anti-diabetic function of
JNK1 in hepatocytes. On the other hand,
JNK1 functions in non-parenchymal liver
cells or extrahepatic tissues appear to be
critical mediators of hepatocellular steatosis
and injury in fatty liver disease. In fact,
selective JNK1 deletion in haematopoietic
cells prevented hepatic inﬂammation and
the ﬁbrosis induced by a HFD or a choline-
deﬁcient L-amino acid-deﬁned diet, respect-
ively, in mice. Therefore, strong evidence
concludes that JNK1 in (hepatic) macro-
phages (Kupffer cells) contributes to the
ﬁbrotic response in NAFLD. Furthermore,
studies indicate that the effects of JNK1 in
adipocytes and cells of the nervous system
promote the development of the metabolic
syndrome and the progression of NAFLD,
whereas JNK1 in muscle cells might
prevent these pathologies.8
These ﬁndings of JNK functions in
NAFLD teach us that for the treatment of
liver ﬁbrosis, speciﬁc cells and deﬁned
molecular pathways must be precisely tar-
geted because even within the same cell
type, different isoforms of the same MAPK
may exhibit completely opposite effects.
Similarly, transcription factor nuclear
factor-κB (NF-κB), another master regulator
of hepatocellular injury, liver ﬁbrosis and
HCC, has been shown to act as a two-edged
sword, and the inhibition of distinct compo-
nents of the NF-κB signalling cascade may
also negatively impact hepatic injury and
ﬁbrosis.9 Further examples include cyto-
kines, such as interferon-gamma (IFN-γ),
transforming growth factor β 1 (TGF-β 1)
and Interleukin-10 (IL-10), that have been
shown to have pleiotropic activities with
effects in one cell type being counterba-
lanced by opposite effects in a neighbouring
cell type.10 Therefore, systemic inhibition of
such cytokines or broad intervention into
signalling pathways may have mixed effects
on hepatic ﬁbrogenesis or may even be detri-
mental, such as in carcinogenesis.
Over the past few years, homing devices
on each and every hepatic cell type have
been developed.10 For example, antibodies
and peptides binding to the platelet-derived
growth factor receptor or synaptophysin
receptor, or coupling mannose-6-phosphate
(M6P) to albumin to create a molecule that
binds to the M6P/insulin-like growth factor
II receptor, provide an important step
towards a HSC-speciﬁc treatment.10 These
magic bullets can be used to target deﬁned
molecular pathways in speciﬁc cells to treat
liver ﬁbrosis in patients with chronic liver
disease. The study by Zhao et al5 provides
the molecular basis to consider HSC-speciﬁc
Jnk1 inhibition as a promising therapeutic
strategy. However, the optimal targets or
cells may vary depending on the type of
liver disease, phase of hepatic injury or spe-
ciﬁc patient characteristics. This problem
will require the application of magic bullets
with various types of cell speciﬁcity and
molecular targets. In addition, combinations
of multiple magic bullets may be used to hit
ﬁbrosis in the crossﬁre from varied direc-
tions, whereas shotgun attacks from only
one side do not appear useful.
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